Bristol-Myers Squibb Price Target Raised to $45.00 at Jefferies Group (BMY)
Jefferies Group boosted their target price on shares of Bristol-Myers Squibb (NYSE:BMY) from $43.50 to $45.00 in a research note issued on Monday. The firm currently has a “hold” rating on the stock. Jefferies Group’s price target suggests a potential downside of 8.52% from the company’s current price.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.49% during mid-day trading on Monday, hitting $49.43. The stock had a trading volume of 1,136,063 shares. Bristol-Myers Squibb has a 52-week low of $41.11 and a 52-week high of $57.49. The stock has a 50-day moving average of $48.99 and a 200-day moving average of $50.54. The company has a market cap of $81.950 billion and a P/E ratio of 30.55.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company’s quarterly revenue was down 3.9% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on BMY. Analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Friday, July 25th. They now have a $52.00 price target on the stock. Separately, analysts at MKM Partners raised their price target on shares of Bristol-Myers Squibb from $29.00 to $34.00 in a research note on Friday, July 25th. They now have a “sell” rating on the stock. Finally, analysts at Leerink Swann cut their price target on shares of Bristol-Myers Squibb from $62.00 to $55.00 in a research note on Tuesday, July 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $51.81.
In other Bristol-Myers Squibb news, CFO Charles A. Bancroft unloaded 67,621 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $51.06, for a total transaction of $3,452,728.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.